Pituitary incidentalomas: the clinical picture, diagnostics, differential diagnostics, and methods of treatment

Incidentalomas are the most common neoplasms in the hypothalamic-pituitary region. Diagnostics, treatment strategy, and indications for the surgical intervention on the patients with these tumours pose a serious challenge for a wide circle of specialists. The diagnostic problems arise from the absence of the specific clinical signs and symptoms as well as the reliable biochemical markers of the disease. The modern laboratory methods do not allow to reveal the pathological hormonal secretion during the diagnostic study, predisposition of the neoplasm to the invasive and infiltrative growth, and signs of its «aggressiveness». This considerably complicates the choice of the optimal surgical strategy and the evaluation of the long-term results of the treatment. Bearing in mind the importance of the problem under consideration, the working group was set up for the development of federal recommendations on the treatment of pituitary incidentalomas based on the principles of evidence-based medicine. The experience accumulated by the domestic and international experts was summarized in the federal clinical guidelines on pituitary incidentalomas containing the available information about these neoplasms.

pituitary incidentalomas, diagnostics, differential diagnostics, surgical treatment, pharmacotherapy

1. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490. doi: 10.1136/bmj.328.7454.1490.

2. Swiglo BA, Murad MH, Schunemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93(3):666-673. doi: 10.1210/jc.2007-1907.

3. Fernandez-Balsells MM, Murad MH, Barwise A, et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2011;96(4):905-912. doi: 10.1210/jc.2010-1054.

4. Feldkamp J, Santen R, Harms E, et al. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin Endocrinol (Oxf). 1999;51(1):109-113.

5. Kazunori A, Tominaga A, Sugiyama K, et al. Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg. 2006;104(6):884-891. doi: 10.3171/jns.2006.104.6.884.

6. Sanno N, Oyama K, Tahara S, et al. A survey of pituitary incidentaloma in Japan. Eur J Endocrinol. 2003;149(2):123-127. doi: 10.1530/eje.0.1490123.

7. Fainstein Day P, Guitelman M, Artese R, et al. Retrospective multicentric study of pituitary incidentalomas. Pituitary. 2004;7(3):145-148. doi: 10.1007/s11102-005-1757-1.

8. Reincke M, Allolio B, Saeger W, et al. The ‘incidentaloma’ of the pituitary gland. Is neurosurgery required? JAMA. 1990;263(20):2772-2776.

9. Donovan LE, Corenblum B. The natural history of the pituitary incidentaloma. Arch Intern Med. 1995;155(2):181-183.

10. Freda PU, Post KD. Differential diagnosis of sellar masses. Endocrinol Metab Clin North Am. 1999;6:28(1):81-117.

11. Zada G, Lin N, Ojerholm E, et al. Craniopharyngioma and other cystic epithelial lesions of the sellar region: a review of clinical, imaging, and histopathological relationships. Neurosurg Focus. 2010;28(4):E4. doi: 10.3171/2010.2.FOCUS09318.

12. Kanter AS, Sansur CA, Jane JAJr, Laws ERJr. Rathke’s cleft cysts. Front Horm Res. 2006;34:127-157. doi: 10.1159/000091579.

13. Black PM, Hsu DW, Klibanski A, et al. Hormone production in clinically nonfunctioning pituitary adenomas. J Neurosurg. 1987;66(2):244-250. doi: 10.3171/jns.1987.66.2.0244.

14. Esiri MM, Adams CB, Burke C, Underdown R. Pituitary adenomas: immunohistology and ultrastructural analysis of 118 tumors. Acta Neuropathol. 1983;62(1-2):1-14.

15. Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 2006;111(1):1-7. doi: 10.1007/s00401-005-1093-6.

16. Molitch ME. Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin North Am. 2008;37(1):151-171, xi. doi: 10.1016/j.ecl.2007.10.011.

17. Wolpert SM, Molitch ME, Goldman JA, Wood JB. Size, shape, and appearance of the normal female pituitary gland. AJR Am J Roentgenol. 1984;143(2):377-381. doi: 10.2214/ajr.143.2.377.

18. Chambers EF, Turski PA, LaMasters D, Newton TH. Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes. Radiology. 1982;144(1):109-113. doi: 10.1148/radiology.144.1.7089241.

19. Peyster RG, Adler LP, Viscarello RR, et al. CT of the normal pituitary gland. Neuroradiology. 1986;28(2):161-165.

20. Hall WA, Luciano MG, Doppman JL, et al. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med. 1994;120(10):817-820.

21. Nammour GM, Ybarra J, Naheedy MH, et al. Incidental pituitary macroadenoma: a population-based study. Am J Med Sci. 1997;314(5):287-291.

22. Yue NC, Longstreth WTJr, Elster AD, et al. Clinically serious abnormalities found incidentally at MR imaging of the brain: data from the Cardiovascular Health Study. Radiology. 1997;202(1):41-46. doi: 10.1148/radiology.202.1.8988190.

23. Igarashi T, Saeki N, Yamaura A. Long-term Magnetic Resonance Imaging Follow-up of Asymptomatic Sellar Tumors -Their Natural History and Surgical Indications&mdash. Neurol Med Chir (Tokyo). 1999;39(8):592-599. doi: 10.2176/nmc.39.592.

24. Karavitaki N, Collison K, Halliday J, et al. What is the natural history of nonoperated nonfunctioning pituitary adenomas? Clin Endocrinol (Oxf). 2007;67(6):938-943. doi: 10.1111/j.1365-2265.2007.02990.x.

25. Dekkers OM, Hammer S, de Keizer RJW, et al. The natural course of non-functioning pituitary macroadenomas. Eur J Endocrinol. 2007;156(2):217-224. doi: 10.1530/eje.1.02334.

26. Nishizawa S, Ohta S, Yokoyama T, Uemura K. Therapeutic Strategy for Incidentally Found Pituitary Tumors («Pituitary Incidentalomas»). Neurosurgery. 1998;43(6):1344-1348.

27. Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91(12):4769-4775. doi: 10.1210/jc.2006-1668.

28. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-382. doi: 10.1111/j.1365-2265.2009.03667.x.

29. Raappana A, Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab. 2010;95(9):4268-4275. doi: 10.1210/jc.2010-0537.

30. Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006;154(5):753-758. doi: 10.1530/eje.1.02107.

31. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006;65(2):265-273. doi: 10.1111/j.1365-2265.2006.02562.x.

32. Angeli A, Terzolo M. Adrenal incidentaloma--a modern disease with old complications. J Clin Endocrinol Metab. 2002;87(11):4869-4871. doi: 10.1210/jc.2002-021436.

33. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93(5):1526-1540. doi: 10.1210/jc.2008-0125.

34. Karavitaki N, Ansorge O, Wass JA. Silent corticotroph adenomas. Arq Bras Endocrinol Metabol. 2007;51(8):1314-1318.

35. Yuen KC, Cook DM, Sahasranam P, et al. Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels. Clin Endocrinol (Oxf). 2008;69(2):292-298. doi: 10.1111/j.1365-2265.2008.03201.x.

36. Molitch ME, Clemmons DR, Malozowski S, et al. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91(5):1621-1634. doi: 10.1210/jc.2005-2227.

37. Gruber A, Clayton J, Kumar S, et al. Pituitary apoplexy: retrospective review of 30 patients-is surgical intervention always necessary? Br J Neurosurg. 2006;20(6):379-385. doi: 10.1080/02688690601046678.

38. Barker FG, 2nd, Klibanski A, Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab. 2003;88(10):4709-4719. doi: 10.1210/jc.2003-030461.

39. Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly -the experience of a dedicated pituitary surgeon. QJM. 1999;92(12):741-745.

40. Arafah BM, Kailani SH, Nekl KE, et al. Immediate recovery of pituitary function after transsphenoidal resection of pituitary macroadenomas. J Clin Endocrinol Metab. 1994;79(2):348-354. doi: 10.1210/jcem.79.2.8045946.

41. Arafah BM. Reversible hypopituitarism in patients with large nonfunctioning pituitary adenomas. J Clin Endocrinol Metab. 1986;62(6):1173-1179. doi: 10.1210/jcem-62-6-1173.

42. Greenman Y, Tordjman K, Osher E, et al. Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth. Clin Endocrinol (Oxf). 2005;63(1):39-44. doi: 10.1111/j.1365-2265.2005.02295.x.

43. Вакс ВВ. Клинически «неактивные» опухоли гипофиза: клинико-морфологические особенности, диагностики, лечения. Материалы Российской научно-практической конференции «Заболевания гипоталамо-гипофизарной системы». Под ред. акад. И.И. Дедова. М. ٢٠٠١;٣٧-٤٥. [Vaks VV. Klinicheski «neaktivnye» opukholi gipofiza: kliniko-morfologicheskie osobennosti, diagnostiki, lecheniya. Proceedings of Russian scientific congress “Diseases of the hypothalamus and pituitary system”. Ed by I.I. Dedov. Moscow; 2001;37-45. (In Russ.)].

44. Molitch ME. Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma. J Clin Endocrinol Metab. 1995;80(1):3-6. doi: 10.1210/jcem.80.1.7829630.

45. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement. J Clin Endocrinol Metab. 2003;88(12):5593-5602. doi:10.1210/jc.2003-030871.

46. Findling JW, Raff H. Cushing’s Syndrome: important issues in diagnosis and management. J Clin Endocrinol Metab. 2006;91(10):3746-3753. doi: 10.1210/jc.2006-0997.

47. Carroll T, Raff H, Findling JW. Late-night salivary cortisol measurement in the diagnosis of Cushing’s syndrome. Nat Clin Pract Endocrinol Metab. 2008;4(6):344-350. doi: 10.1038/ncpendmet0837.

48. Scheithauer BW, Jaap AJ, Horvath E, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47(3):723-729; discussion 729-730.

49. Bradley KJ, Wass JAH, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf). 2003;58(1):59-64. doi: 10.1046/j.1365-2265.2003.01674.x.

50. Doerfler A, Richter G. Lesions within and around the Pituitary. Clin Neuroradiol. 2008;18(1):5-18. doi: 10.1007/s00062-008-8001-0.

51. Дедов ИИ, Вакс ВВ. Клиническая нейроэндокринология. М. 2011;170-204. [Dedov II, Vaks VV. Clinical neuroendocrinology. Moscow. 2011;170-204. (In Russ.)].

52. Chanson P, Young J. Pituitary Incidentalomas. The Endocrinologist. 2003;13(2):124-135.

53. Thomas R, Shenoy K, Seshadri MS, et al. Visual field defects in non-functioning pituitary adenomas. Indian J Ophthalmol. 2002;50(2):127-130.

54. Кадашев БА. Аденомы гипофиза: клиника, диагностика, лечение. Тверь: ООО «Триада Х». ٢٠٠٧;٣٦٨. [Kadashev BA. Pituitary adenomas: clinical presentation, diagnosis, treatment. Tver’: Triada X. 2007;368 (In Russ.)].

55. Lohmann T, Trantakis C, Biesold M, et al. Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline. Pituitary. 2001;4(3): 173-178.

56. Dekkers OM, Pereira AM, Romijn JA. Treatment and follow-up of clinically nonfunctioning pituitary macroadenomas. J Clin Endocrinol Metab. 2008;93(10):3717-3726. doi: 10.1210/jc.2008-0643.

57. Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007;357(18):1821-1828. doi: 10.1056/NEJMoa070972.

58. Chacko AG, Chandy MJ. Incidental pituitary macroadenomas. Br J Neurosurg. 1992;6(3):233-236.

59. Вакс ВВ, Кадашев СЮ, Касумова СЮ. Отдаленные результаты послеоперационного лечения при «неактивных» аденомах гипофиза. Проблемы эндокринологии. 2001;47(1):16-19. [Vaks VV, Kadashev SYu, Kasumova SYu. Otdalennye rezul’taty posleoperatsionnogo lecheniya pri «neaktivnykh» adenomakh gipofiza. Problemy endokrinologii. 2001;47(1):16-19. (In Russ.)].

60. Bronstein MD, Paraiba DB, Jallad RS. Management of pituitary tumors in pregnancy. Nat Rev Endocrinol. 2011;7(5):301-310. doi: 10.1038/nrendo.2011.38.

61. Dinc H, Esen F, Demirci A, et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol. 1998;39(1):64-69.

62. Вакс ВВ, Дедов ИИ. Возможности медикаментозной терапии опухолей гипофиза. Вопросы нейрохирургии им. Н.Н. Бурденко. 2005;69(2):30-37. [Vaks VV, Dedov II. Vozmozhnosti medikamentoznoy terapii opukholey gipofiza. Zhurnal voprosy neirokhirurgii imeni N.N. Burdenko. 2005;69(2):30-37. (In Russ.)].

63. Pivonello R, Matrone C, Filippella M, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004;89(4):1674-1683. doi: 10.1210/jc.2003-030859.

64. Shomali ME, Katznelson L. Medical therapy of gonadotropin-producing and nonfunctioning pituitary adenomas. Pituitary. 2002;5(2):89-98.

65. Merola B, Colao A, Ferone D, et al. Effects of a Chronic Treatment with Octreotide in Patients with Functionless Pituitary Adenomas. Horm Res. 1993;40(4):149-155. doi: 10.1159/000183785.

66. Bruin TWd, Kwekkeboom DJ, Verlaat JWV, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992;75(5):1310-1317. doi: doi:10.1210/jcem.75.5.1430093.

67. Colao A, Di Somma C, Pivonello R, et al. Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer. 2008;15(4):905-915. doi: 10.1677/ERC-08-0181.

68. Colao A, Filippella M, Di Somma C, et al. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine. 2003;20(3):279-283. doi: 10.1385/ENDO:20:3:279.